RotaShield Return? Biovirx Plans Global Reintroduction Of Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovirx obtained a global license from NIH; the firm will seek a partner for the U.S. and Europe. Wyeth withdrew the rotavirus vaccine in July 1999 due to an increased risk of intussusception in vaccinated infants.
You may also be interested in...
RotaShield Re-Submission May Include Intussusception Data Re-Analysis
Biovirx and IDT have signed a manufacturing agreement for the troubled rotavirus vaccine.
RotaShield Re-Submission May Include Intussusception Data Re-Analysis
Biovirx and IDT have signed a manufacturing agreement for the troubled rotavirus vaccine.
Merck Rotavirus Vaccine Has Low Risk Of Intussusception, FDA Review Says
Discrepancies in reports of follow-up time prevent the agency from reaching a conclusion on RotaTeq’s efficacy.